4.7 Article

A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance

期刊

SCIENTIFIC REPORTS
卷 6, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/srep22791

关键词

-

资金

  1. Australian National Health & Medical Research Council
  2. NHMRC Australia Fellowship [AF51104]

向作者/读者索取更多资源

Fusion of the viral envelope with host cell membranes is an essential step in the life cycle of all enveloped viruses. Despite such a clear target for antiviral drug development, few anti-fusion drugs have progressed to market. One significant hurdle is the absence of a generic, high-throughput, reproducible fusion assay. Here we report that real time, label-free measurement of cellular electrical impedance can quantify cell-cell fusion mediated by either individually expressed recombinant viral fusion proteins, or native virus infection. We validated this approach for all three classes of viral fusion and demonstrated utility in quantifying fusion inhibition using antibodies and small molecule inhibitors specific for dengue virus and respiratory syncytial virus.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems

Ahmed O. Shalash, Armira Azuar, Harrison Y. R. Madge, Naphak Modhiran, Alberto A. Amarilla, Benjamin Liang, Alexander A. Khromykh, Waleed M. Hussein, Keith J. Chappell, Daniel Watterson, Paul R. Young, Mariusz Skwarczynski, Istvan Toth

Summary: The SARS-CoV-2 virus has caused a global crisis with billions of infections and millions of deaths. Current DNA and mRNA vaccines have shown decreased efficacy over time, especially the Pfizer BNT162 vaccine. Variant strains have further reduced vaccine effectiveness. Peptide vaccines offer an alternative solution with greater stability and flexibility to target emerging strains.

PHARMACEUTICS (2022)

Article Immunology

Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern

Christopher L. D. McMillan, Armira Azuar, Jovin J. Y. Choo, Naphak Modhiran, Alberto A. Amarilla, Ariel Isaacs, Kate E. Honeyman, Stacey T. M. Cheung, Benjamin Liang, Maria J. Wurm, Paco Pino, Joeri Kint, Germain J. P. Fernando, Michael J. Landsberg, Alexander A. Khromykh, Jody Hobson-Peters, Daniel Watterson, Paul R. Young, David A. Muller

Summary: The study investigated a novel vaccination strategy using a modified HexaPro S protein subunit vaccine, which generated potent antibody responses capable of neutralizing various SARS-CoV-2 variants in mice. The results demonstrated the potential of this alternative vaccination approach to mitigate the impact of emerging viral variants.

VACCINES (2022)

Article Plant Sciences

Isolation and Characterization of Werneria Chromene and Dihydroxyacidissimol from Burkillanthus malaccensis (Ridl.) Swingle

Masyitah Zulkipli, Nuzum Mahbub, Ayesha Fatima, Stefanie Lim Wan-Lin, Teng-Jin Khoo, Tooba Mahboob, Mogana Rajagopal, Chandramathi Samudi, Gheetanjali Kathirvalu, Nor Hayati Abdullah, Ana Rita Pinho, Sonia M. R. Oliveira, Maria de Lourdes Pereira, Mohammed Rahmatullah, Anamul Hasan, Alok K. Paul, Mark S. Butler, Muhammad Nawaz, Polrat Wilairatana, Veeranoot Nissapatorn, Christophe Wiart

Summary: The secondary metabolites of Burkillanthus malaccensis (Ridl.) Swingle, an endemic plant from the Rutaceae family in the Malaysian rainforest, were investigated for their potential antibacterial and antibiotic-potentiating activities. The extracts from different parts of the plant showed varying degrees of inhibition against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Chromatographic separations led to the identification of werneria chromene and dihydroxyacidissiminol, which exhibited antibacterial and anti-SARS-CoV-2 activities. This study highlights the potential of Burkillanthus malaccensis (Ridl.) Swingle as a natural source of antibiotics and anti-SARS-CoV-2 agents.

PLANTS-BASEL (2022)

Article Immunology

Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern

Christopher L. D. McMillan, Alberto A. Amarilla, Naphak Modhiran, Jovin J. Y. Choo, Armira Azuar, Kate E. Honeyman, Alexander A. Khromykh, Paul R. Young, Daniel Watterson, David A. Muller

Summary: The ongoing SARS-CoV-2 pandemic has posed a significant global health challenge, with emerging variants causing reduced vaccine efficacy and the need for booster immunizations. Delivery of a subunit vaccine through a high-density microarray patch (HD-MAP) has been shown to induce potent immunity and maintain neutralization against various variants.

VACCINE (2022)

Article Immunology

Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants

Ariel Isaacs, Alberto A. Amarilla, Julio Aguado, Naphak Modhiran, Eduardo A. Albornoz, Alireza A. Baradar, Christopher L. D. McMillan, Jovin J. Y. Choo, Adi Idris, Aroon Supramaniam, Nigel A. J. McMillan, David A. Muller, Paul R. Young, Trent M. Woodruff, Ernst J. Wolvetang, Keith J. Chappell, Daniel Watterson

Summary: Due to the high mutability of SARS-CoV-2, current spike-specific immune detection methods have limitations. This study demonstrates the use of nucleocapsid-specific detection in multiple assays to detect different SARS-CoV-2 variants, providing a universal target for addressing COVID-19 mutations.

FRONTIERS IN IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein

Eduardo A. Albornoz, Alberto A. Amarilla, Naphak Modhiran, Sandra Parker, Xaria X. Li, Danushka K. Wijesundara, Julio Aguado, Adriana Pliego Zamora, Christopher L. D. McMillan, Benjamin Liang, Nias Y. G. Peng, Julian D. J. Sng, Fatema Tuj Saima, Jenny N. Fung, John D. Lee, Devina Paramitha, Rhys Parry, Michael S. Avumegah, Ariel Isaacs, Martin W. Lo, Zaray Miranda-Chacon, Daniella Bradshaw, Constanza Salinas-Rebolledo, Niwanthi W. Rajapakse, Ernst J. Wolvetang, Trent P. Munro, Alejandro Rojas-Fernandez, Paul R. Young, Katryn J. Stacey, Alexander A. Khromykh, Keith J. Chappell, Daniel Watterson, Trent M. Woodruff

Summary: COVID-19 infection may lead to neurological symptoms similar to Parkinson's disease. The study found that SARS-CoV-2 and spike protein can directly activate the NLRP3 inflammasome in microglial cells, which may contribute to the development of neuroinflammation.

MOLECULAR PSYCHIATRY (2023)

Article Cell Biology

A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections

Mark A. T. Blaskovich, Karl A. Hansford, Mark S. Butler, Soumya Ramu, Angela M. Kavanagh, Angie M. Jarrad, Anggia Prasetyoputri, Miranda E. Pitt, Johnny X. Huang, Fredrik Lindahl, Zyta M. Ziora, Tanya Bradford, Craig Muldoon, Premraj Rajaratnam, Ruby Pelingon, David J. Edwards, Bing Zhang, Maite Amado, Alysha G. Elliott, Johannes Zuegg, Lachlan Coin, Anne-Kathrin Woischnig, Nina Khanna, Elena Breidenstein, Anna Stincone, Clive Mason, Nawaz Khan, Hye-Kyung Cho, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, Robin Patel, Mandy Wootton, Meagan L. James, Melanie L. Hutton, Dena Lyras, Abiodun D. Ogunniyi, Layla K. Mahdi, Darren J. Trott, Xiaoqian Wu, Samantha Niles, Kim Lewis, Jordan R. Smith, Katie E. Barber, Juwon Yim, Seth Alan Rice, Michael J. Rybak, Chad R. Ishmael, Kellyn R. Hori, Nicholas M. Bernthal, Kevin P. Francis, Jason A. Roberts, David L. Paterson, Matthew A. Cooper

Summary: Drug-resistant Gram-positive bacterial infections remain a significant burden on the public health system. We have developed an effective antibiotic, MCC5145, which shows excellent potency against MRSA and other Gram-positive bacteria, with low toxicity and improved activity against biofilms. It also has a low propensity for developing drug resistance.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Hematology

Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light

Jody Hobson-Peters, Alberto A. Amarilla, Lina Rustanti, Denese C. Marks, Eileen Roulis, Alexander A. Khromykh, Naphak Modhiran, Daniel Watterson, Stefan Reichenberg, Frank Tolksdorf, Chryslain Sumian, Axel Seltsam, Ute Gravemann, Helen M. Faddy

Summary: The THERAFLEX MB-Plasma and THERAFLEX UV-Platelets systems were found to effectively reduce the infectivity of SARS-CoV-2 in plasma and platelets, respectively.

TRANSFUSION (2023)

Article Computer Science, Information Systems

CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Hardik A. Jain, Vinti Agarwal, Chaarvi Bansal, Anupama Kumar, Faheem FaheemFaheem, Muzaffar-Ur-Rehman Mohammed, Sankaranarayanan Murugesan, Moana M. Simpson, Avinash V. Karpe, Rohitash Chandra, Christopher A. MacRaild, Ian K. Styles, Amanda L. Peterson, Matthew A. Cooper, Carl M. J. Kirkpatrick, Rohan M. Shah, Enzo A. Palombo, Natalie L. Trevaskis, Darren J. Creek, Seshadri S. Vasan

Summary: Repurposing approved drugs is an excellent strategy to quickly obtain safe and effective COVID-19 treatments. To address this, the CoviRx.org platform provides a user-friendly interface for analyzing and filtering large quantities of data, while encouraging users to submit their findings. This will help combat the pandemic and expand to other diseases.
Article Biochemistry & Molecular Biology

Purification of PaTx-II from the Venom of the Australian King Brown Snake and Characterization of Its Antimicrobial and Wound Healing Activities

Ramar Perumal Samy, Stephen P. P. Mackessy, Alagarmalai Jeyasankar, Mano Ranjana Ponraj, Octavio Luiz Franco, Matthew A. A. Cooper, Matheswaran Kandasamy, Tapan Kumar Mohanta, Jebasingh Bhagavathsingh, Sakthivel Vaiyapuri

Summary: PaTx-II, an active component from the venom of the Mulga Snake, showed potent antimicrobial activity and promoted wound healing.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biotechnology & Applied Microbiology

Antibiotics in the clinical pipeline as of December 2022

Mark S. Butler, Ian R. Henderson, Robert J. Capon, Mark A. T. Blaskovich

Summary: The global need for new antibacterial drugs to combat drug-resistant bacterial infections is receiving significant attention, leading to numerous funding, policy, and legislative initiatives to support antibacterial research and development. This review assesses the impact of these programs by analyzing the clinical development of various types of antibacterial drugs and the number of drug approvals in recent years. The findings show an increasing number of early-stage candidates and a presence of novel antibacterial compounds, particularly targeting Gram-negative bacteria.

JOURNAL OF ANTIBIOTICS (2023)

Article Biology

Synthesis of vancomycin fluorescent probes that retain antimicrobial activity, identify Gram-positive bacteria, and detect Gram-negative outer membrane damage

Bing Zhang, Wanida Phetsang, M. Rhia L. Stone, Sanjaya Kc, Mark S. S. Butler, Matthew A. A. Cooper, Alysha G. G. Elliott, Urszula Lapinska, Margaritis Voliotis, Krasimira Tsaneva-Atanasova, Stefano Pagliara, Mark A. T. Blaskovich

Summary: Antimicrobial resistance is a critical concern for human health, and this study presents the development of vancomycin fluorescent probes that can be used for detecting and visualizing Gram-positive bacteria as well as for measuring outer membrane permeabilization in Gram-negative bacteria. The probes were synthesized by modifying vancomycin with an azide substituent, enabling it to undergo copper-catalyzed azide-alkyne cycloaddition reactions. The probes exhibited similar antibacterial profiles to the parent vancomycin antibiotic and were versatile tools for various detection and imaging techniques.

COMMUNICATIONS BIOLOGY (2023)

Article Plant Sciences

Turonicin A, an Antifungal Linear Polyene Polyketide from an Australian Streptomyces sp.

Rachel Chen, Scott A. Minns, John A. Kalaitzis, Mark S. Butler, Maira Rosin, Daniel Vuong, Soo Sum Lean, Yit-Heng Chooi, Ernest Lacey, Andrew M. Piggott

Summary: Researchers discovered TuronicinA (1) from Streptomyces sp. MST-123921 in soil, which showed potent antimicrobial activity against fungi and bacteria without cytotoxicity to human cells.

JOURNAL OF NATURAL PRODUCTS (2023)

Article Chemistry, Medicinal

Nanoscaled Discovery of a Shunt Rifamycin from Salinispora arenicola Using a Three-Color GFP-Tagged Staphylococcus aureus Macrophage Infection Assay

Nhan T. Pham, Joana Alves, Fiona A. Sargison, Reiko Cullum, Jan Wildenhain, William Fenical, Mark S. Butler, David A. Mead, Brendan M. Duggan, J. Ross Fitzgerald, James J. La Clair, Manfred Auer

Summary: Antimicrobial resistance is a global public health threat, and finding new therapeutics to treat infections caused by multi-drug resistant bacteria is urgent. This study presents a fluorescence imaging assay to monitor macrophage infection by S. aureus, which can help identify potential antibiotics. The assay combined with nanoscaled chemical analyses led to the discovery of a new active rifamycin analogue. This finding offers a promising approach for identifying antimicrobial compounds with intracellular activity in macrophages.

ACS INFECTIOUS DISEASES (2023)

Review Biochemistry & Molecular Biology

Natural products as anthelmintics: safeguarding animal health

Angela A. Salim, Mark S. Butler, Mark A. T. Blaskovich, Ian R. Henderson, Robert J. Capon

Summary: This review summarizes all natural products (500 compounds, including 17 semi-synthetic derivatives) reported in the primary literature up to December 2022 that have been shown to inhibit the egg hatching, motility, larval development, and/or survival of helminths (nematodes, flukes, and tapeworms). These parasites infect and harm the health, welfare, productivity, and lives of commercial livestock, companion animals, and other valuable, endangered, and exotic animals. The review focuses on chemical structures, source organisms, and anthelmintic properties, including the target species, animal hosts, and potency measures used in bioassays.

NATURAL PRODUCT REPORTS (2023)

暂无数据